Metabolic Syndrome and Kidney Health: What You Need to Know
"Does metabolic syndrome's impact on blood flow affect kidney collateral circulation? A new study explores the connection."
Metabolic syndrome, a cluster of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels, is a growing concern worldwide. While its effects on cardiovascular health are well-documented, its impact on kidney health, particularly in the presence of renal artery stenosis (RAS), is an area of ongoing research.
Renal artery stenosis, a narrowing of the arteries carrying blood to the kidneys, can lead to decreased blood supply and subsequent kidney damage. To compensate, the body may develop collateral circulation, creating new pathways for blood to reach the affected kidney. However, the effectiveness of this process can be influenced by factors like obesity and metabolic syndrome.
This article delves into a recent study investigating whether metabolic syndrome affects the development of collateral circulation in kidneys experiencing RAS. By understanding this complex interaction, we can gain insights into how to protect kidney function in individuals with metabolic syndrome and RAS.
From Metabolic Syndrome to CKM
The framing of cardiometabolic disease has evolved from Reaven syndrome, also called “syndrome X,” through metabolic syndrome to cardiovascular–kidney–metabolic (CKM) syndrome, reflecting broader recognition of connections among these conditions. The CKM framework brings metabolic dysfunction, chronic kidney disease, and cardiovascular disease together as interacting components of a multisystem condition. In 2005, Abate, Chandalia, and colleagues examined links between metabolic syndrome and kidney-stone risk, while Sanchez-Lozada, Tapia, and colleagues explored hyperuricemia in hypertension and kidney disease. Separately, the Developmental Origins of Health and Disease framework describes how maternal and perinatal exposures can affect nephron endowment, vascular function, and metabolic regulation.
Metabolic Syndrome's Impact on Kidney Blood Flow: The Study's Findings
A study published in the American Journal of Hypertension explored the link between metabolic syndrome and renal collateral circulation using a swine model of unilateral RAS. The researchers aimed to determine if metabolic syndrome enhances collateral vessel growth, thereby preserving renal function. Here's a breakdown of their approach and key findings:
- MetS-RAS: Fed a high-fat/high-fructose diet to induce metabolic syndrome, along with unilateral RAS.
- RAS: Fed a standard diet with unilateral RAS.
- Control: Fed a standard diet with no RAS.
Current Research Directions
Recent work has examined kidney injury in pigs with diet-induced metabolic syndrome and renal artery stenosis after 16 weeks, comparing mesenchymal stem/stromal cells with their extracellular-vesicle progeny. Another study investigated low-energy extracorporeal shockwave therapy before revascularization of a stenotic renal artery in pigs and discussed endothelial-to-mesenchymal transition in hypertensive kidney injury. In an observational study of chronic total occlusion, poor coronary collateralization rose across groups meeting zero through five metabolic-syndrome diagnostic criteria, from 7.6% to 51.1%. A 2026 focused narrative review summarizes molecular and cellular mechanisms linking metabolic syndrome to kidney dysfunction and identifies knowledge gaps and potential therapeutic opportunities.
Evidence and Its Limits
Sources describe metabolic syndrome as a cluster that can include central or visceral obesity, hypertension, dyslipidemia, and hyperglycemia, and associate it with kidney dysfunction. A meta-analysis concludes that people with metabolic syndrome and its individual components are at higher risk of renal dysfunction. A 2022 review reports a prevalence of 20–25% and describes possible kidney effects including glomerular hyperfiltration, RAAS activity, microalbuminuria, profibrotic factors, and podocyte injury. However, the evidence is not uniformly settled: a 2023 systematic review and meta-analysis specifically notes that evidence linking metabolic syndrome to CKD has remained inconsistent.
Contrasting Renal Responses
The supplied studies examine different renal interventions and experimental settings, so their findings are not direct comparisons. In one study, unilateral renal sympathectomy was induced by infusing lidocaine into the left renal artery at 0.5 mg/kg/min, with changes compared against the right, non-infused kidney. In a conscious-dog study of renal artery stenosis, indomethacin reduced urinary prostaglandin E excretion by 90% but produced no functional changes in the stenotic kidney. In arachidonate-deficient spontaneously hypertensive rat kidneys, increasing perfusion pressure from 100 to 160 mm Hg raised renal vascular resistance by 32–41%.
- Renal blood flow (RBF) and glomerular filtration rate (GFR)
- Collateral circulation around the renal artery
- Intrarenal microcirculation
- Expression of vascular endothelial growth factor (VEGF)
- Renal fibrosis and stiffness
Protecting Your Kidneys: Key Takeaways
While the study suggests that metabolic syndrome doesn't necessarily hinder collateral vessel formation in the stenotic kidney, it's important to recognize the broader implications for kidney health. The researchers found that even with preserved renal blood flow, metabolic syndrome aggravated renal injury distal to the stenosis.
A Connected Clinical Framework
The evidence supplied includes both reports associating metabolic syndrome with kidney dysfunction and a systematic review describing that association as inconsistent. A 2026 CKM guideline is presented as a step toward addressing the growing burden of this multisystem syndrome in clinical practice. It synthesizes evidence to support screening, diagnosis, and management. Together, these sources point to a broad clinical framework while indicating that the strength of evidence for particular metabolic-syndrome and kidney relationships is not uniform.
Measuring Future CKM Burden
A 2026 medRxiv preprint describes a need for nationally representative estimates of cardiovascular-kidney-metabolic syndrome across the full 1999–2023 NHANES interval. It also identifies estimation of future burden under plausible population scenarios as an open area of work. A separate 2026 article defines CKM syndrome as an American Heart Association framework encompassing cardiovascular disease, chronic kidney disease, obesity, and diabetes. It describes these conditions as linked through a self-reinforcing metabolic-inflammatory cycle.
Putting CKM Into Practice
The CKM framework connects metabolic dysfunction, chronic kidney disease, and cardiovascular disease, whose interacting changes are described as amplifying morbidity and mortality. A 2025 case-based article uses four hypothetical cases to illustrate features of the American Heart Association CKM health construct. Its cases incorporate the CKM staging system, estimates from the PREVENT risk calculator, and clinical approaches tailored to stages and individual risk profiles. The examples include management considerations for a patient with stage 1 obesity.
This highlights the need for a comprehensive approach to managing metabolic syndrome, including lifestyle modifications and medical interventions to address the underlying risk factors. Focusing on healthy eating habits, regular exercise, and weight management can significantly impact overall kidney health.
Ultimately, further research is needed to fully understand the intricate relationship between metabolic syndrome and kidney function. However, this study underscores the importance of proactive kidney care in individuals with metabolic syndrome, emphasizing early detection, intervention, and ongoing management to preserve long-term renal health.